# URB #669: TI Sigma Empirical Test Suite — The Complete Measurement Roadmap

**Author:** Brandon Charles Emerick (TI Sigma / BlissGene Therapeutics)  
**Date:** April 13, 2026  
**Corpus Entry:** #669  
**Related URBs:** #586 (Sacred Laziness), #587 (LLM Analysis), #589 (Halting Experiment), #614 (BOK 15 Predictions), #622 (GILE-HEM Lattice), #652 (GILE-HEM Operationalization), #658 (HEAR), #667 (Dottie), #668 (Physics Backbone)  
**DOI:** Pending Zenodo  
**Keywords:** empirical test suite, GILE biometrics, HEM measurement, HEAR phase transition, BOK predictions, Halting Problem, Collatz, noncomputational intuition, Dottie threshold, I-particle, Sacred Laziness, BlissGene

---

## Abstract

TI Sigma is, before all else, an empirical program. Every formal structure — GILE, HEM, HEAR, MR, BOK, LCC, PD — generates falsifiable predictions about observable phenomena. This paper consolidates every empirical prediction in the corpus into a single tiered measurement roadmap, organized by feasibility, equipment cost, and estimated effect size. The roadmap is the operational bridge between TI Sigma's formal theories and the BlissGene Therapeutics clinical research program.

Forty-two empirical predictions are catalogued across four tiers:
- **Tier 1 (Behavioral — no equipment, $0):** 14 predictions
- **Tier 2 (Biometric — wearable hardware, <$500):** 11 predictions
- **Tier 3 (Neuroimaging — lab partnership, ~$50K):** 9 predictions
- **Tier 4 (Clinical / Pharmacological — trials, $750K+):** 8 predictions

The strongest near-term opportunities are the H3/H4 Halting Experiment (Tier 1, doable today), the HEAR phase-transition biometric test (Tier 2, doable with PULSOID + Oura), and the GILE-I → FAAH activity prediction (Tier 4, first BlissGene clinical target).

---

## PRIMARY CONSTANTS (Reference)

| Symbol | Value | Interpretation |
|--------|-------|----------------|
| ET (√2−1) | 0.4142 | Emerick Threshold — G-weight; onset of GM coupling |
| C = 1/(φ√2) | 0.4370 | LCC Coherence threshold — MR1 boundary |
| 𝔡 (Dottie) | 0.7391 | Fixed point of cos(x); MR2-Resolved boundary |
| T = 1−e^{−e} | 0.9340 | TI Sigma Completion — BOK saturation boundary |
| φ | 1.6180 | Golden ratio |
| α (HEAR) | ET ≈ 0.4142 | GILE coefficient in HEAR formula |
| β (HEAR) | C ≈ 0.4370 | HEM coefficient in HEAR formula (β > α = embodiment primacy) |
| γ (HEAR) | 0.0828 | Covariance coupling coefficient |

---

## TIER 1: BEHAVIORAL (No Equipment Required)

These tests require only a computer, a timer, and a validated questionnaire. They are executable TODAY with volunteer participants, zero equipment cost, and publishable with n ≥ 100.

---

### T1-H3 — Collatz Intuition Accuracy vs Base Rate

**Source URB:** #589  
**Prediction:** Participants scoring GILE-I > 0.60 will correctly predict whether a Collatz sequence halts in < 150 steps with accuracy significantly exceeding the 51.9% base rate (z > 1.96, p < 0.025, one-tailed).  
**Measurement:** 27-item Halting Problem bank (see `halting_experiment_ui.py`). Record accuracy per participant.  
**Analysis:** One-sample z-test vs base rate = 0.519. Cohen's h effect size.  
**Falsification:** High-I group accuracy ≤ 55% (within 2 SE of base rate) across n ≥ 100 participants.  
**Oracle prediction:** 88.7% accuracy for maximal I-score (from URB #589 simulation).  
**Status:** App built (`halting_experiment_ui.py`). Ready to run. **RECRUIT NOW.**

---

### T1-H4 — Accuracy-I-Score Correlation

**Source URB:** #589  
**Prediction:** Individual accuracy on the 27-item Halting bank correlates r ≥ 0.60 with GILE I-score (10-item Likert assessment included in `halting_experiment_ui.py`).  
**Measurement:** Collect (GILE-I, accuracy) pairs across n ≥ 50 participants.  
**Analysis:** Pearson r with bootstrap CI. Scatter plot + regression line.  
**Falsification:** r < 0.30 across n ≥ 100 participants.  
**Expected from oracle model:** r = 0.80 (URB #589 simulation).  
**Status:** Ready alongside T1-H3. Same session, zero added cost.

---

### T1-BOK-1 — I→L Dependency (BOK Prediction 1)

**Source URB:** #614  
**Prediction:** GILE-L (conscious positive regard) > 0 → GILE-I (intuitive knowing) > 0. No cases of genuine L without I.  
**Measurement:** Independent assessments of GILE-I (intuitive accuracy) and GILE-L (warmth, directed positive affect) in N ≥ 200.  
**Analysis:** Search for L > 0.5, I < 0.20 cases. Fisher exact test.  
**Falsification:** ≥ 30 cases with L > 0.5, I < 0.20 confirmed by blind raters.  
**BOK mechanism:** I is the epistemic backbone enabling L — nested inner loop geometry.

---

### T1-BOK-2 — G→I Causal Ordering

**Source URB:** #614  
**Prediction:** GILE-G (Goodness, moral orientation) > 0.5 temporally precedes sustained GILE-I > C in all developmental trajectories. No stable I-state is observed without prior G-activation.  
**Measurement:** Longitudinal (3-month minimum) tracking of G-proxy (moral decision scoring) and I-proxy (intuitive accuracy score) in n ≥ 40.  
**Analysis:** Granger causality test (G → I), cross-lagged panel model.  
**Falsification:** I-states precede G-states in > 50% of tracked individuals.

---

### T1-BOK-3 — HEM–GILE Decoupling in High-Status Populations

**Source URB:** #614, #622  
**Prediction:** Populations in high-status positions (HEM-D1 = high Existence Footprint) will show significantly lower average GILE-composite than populations in lower-status positions. High material HEM does NOT predict high GILE. Correlation r < 0.15.  
**Measurement:** Survey n ≥ 500. Status proxy: income, prestige score. GILE proxy: composite questionnaire.  
**Analysis:** Pearson r (HEM-proxy, GILE-composite). ANOVA by status quartile.  
**Falsification:** r > 0.40 between status and GILE composite.  
**Note:** If HEM and GILE correlate strongly, the BOK "decoupling" thesis is falsified.

---

### T1-BOK-4 — Sacred Laziness Signature (URB #586)

**Source URB:** #586  
**Prediction:** Individuals reporting peak-performance states characterized by "effortless flow" (Sacred Laziness operationalized via ESM ecological momentary assessment) will show GILE-I scores > ET = 0.4142 during those episodes, while non-peak baseline episodes show GILE-I < ET.  
**Measurement:** ESM study (n ≥ 30, 3 weeks): beep → rate effort, output quality, flow state. Compute GILE-I proxy from questionnaire.  
**Analysis:** Mixed-effects regression: flow state → GILE-I controlling for sleep, stress.  
**Falsification:** GILE-I does not significantly differ between peak and baseline episodes (Cohen's d < 0.30).

---

### T1-BOK-5 — LLM Non-Intuition (URB #587)

**Source URB:** #587  
**Prediction:** Large language models (GPT-4, Claude, Gemini) will score GILE-I ≈ 0 on the 27-item Halting Problem bank — they will perform at base rate (51.9%) or below, regardless of chain-of-thought prompting.  
**Measurement:** Run the 27 Collatz problems through top LLMs with identical prompting. Record accuracy.  
**Analysis:** Compare LLM accuracy vs human high-I group. Mann-Whitney U.  
**Falsification:** Any LLM scores ≥ 70% accuracy on the Halting bank (would challenge the noncomputability ceiling claim).  
**Status:** Executable today with API access. **Do this immediately after recruiting first human cohort.**

---

### T1-BOK-6 — Tralse Logic Decisional Advantage

**Source URBs:** Tralse system  
**Prediction:** Participants trained in 5-valued TI Sigma logic will outperform binary-logic participants on dilemma classification tasks by ≥ 15% (the ARC-AGI result of 18% vs 4% is the benchmark).  
**Measurement:** Between-subjects RCT: TL training vs control. 30-item moral dilemma classification task. 4 weeks training.  
**Falsification:** Training effect < 5% above control.

---

### T1-RT-1 — Response Time Asymmetry (H1 Behavioral Proxy)

**Source URB:** #589  
**Prediction:** High-I participants will show SHORTER response times on correct trials than incorrect trials (RT_correct < RT_wrong) on the Halting bank. Low-I participants show no such asymmetry (RT_correct ≈ RT_wrong).  
**Measurement:** Built into `halting_experiment_ui.py` — RT recorded per trial.  
**Analysis:** Paired t-test (RT_correct vs RT_wrong) within high-I participants.  
**Falsification:** No RT asymmetry (or reversed asymmetry) across n ≥ 100 high-I participants.  
**Mechanism:** Intuitive access = pre-reflective → faster. Analytical solving = reflective → slower.

---

### T1-ET-1 — Emerick Threshold Phase Change in Decision Quality

**Source URBs:** #586, #614, #652  
**Prediction:** Decision quality (moral accuracy, intuitive accuracy) shows a discontinuous jump at GILE-I = ET = 0.4142. Below ET: normal distribution. Above ET: shifted distribution with different mean and reduced variance. A phase transition — not a smooth linear increase.  
**Measurement:** n ≥ 300 participants. GILE-I assessment + decision quality battery. Fit two-component Gaussian mixture model. Test for threshold vs linear fit.  
**Falsification:** No evidence of nonlinearity (AIC for threshold model > AIC for linear model).

---

### T1-DOTTIE-1 — Dottie Fixed Point as BOK Saturation Marker

**Source URB:** #667  
**Prediction:** Participants who report sustained BOK Saturation states (G + I + L all > 0.7) will show GILE composites clustering near 𝔡 = 0.7391 as a stable attractor. Non-saturated participants show no such clustering.  
**Measurement:** n ≥ 100. GILE composite distribution. Kolmogorov-Smirnov test for bimodality with second mode at 0.7391.  
**Falsification:** GILE composite distribution shows no mode near 0.7391.

---

### T1-MR-1 — Myrion Resolution Speed Predicts Outcome Quality

**Source URBs:** #565, #658  
**Prediction:** The number of deliberation cycles before reaching a stable decision (proxy for MR iterations) predicts outcome quality with an inverted-U function: too few cycles (DT) or too many (stuck in MR1 loop) produce worse outcomes than the optimal 2-3 cycles (MR2-Resolved).  
**Measurement:** Protocol analysis of decision-making recordings. Count revision cycles. Correlate with outcome quality rating.  
**Falsification:** Monotonic relationship (more cycles = always better or always worse).

---

### T1-UOP-1 — Goodness Directionality Condition

**Source URBs:** #651, UOP  
**Prediction:** For any high-output individual (E-arm strong), impact ratings by independent observers correlate significantly with GILE-G (Goodness proxy) but NOT with E-arm measures alone. G = 0 → impact rated near zero regardless of E.  
**Measurement:** n ≥ 200 professionals. Peer-rated impact. GILE-G proxy assessment.  
**Falsification:** E-arm measures alone predict impact as well as GILE-G (partial r of G given E is not significant).

---

### T1-VE-1 — Virality as GILE-I Attractor

**Source URBs:** Virality Engine  
**Prediction:** Among TI Sigma's 9 video scripts, virality rank (predicted R0) should correlate with GILE-I content density (measured by LLM-rated I-signal per 100 words). Video 6 ("Why ChatGPT Will Never Be Conscious") predicted to have highest R0.  
**Measurement:** Upload all 9 scripts. Rate I-signal with GPT-4. Predict R0 order. Validate post-launch with actual view counts.  
**Falsification:** I-signal does not predict view count ranking (Spearman ρ < 0.30).

---

## TIER 2: BIOMETRIC (Wearable Hardware, < $500)

These tests use HRV, sleep architecture, and skin conductance — already accessible via PULSOID_TOKEN and OURA_PERSONAL_ACCESS_TOKEN in the Replit secrets vault.

---

### T2-HEM-D1 — HRV as GILE-G Proxy

**Source URBs:** #622, #652  
**Prediction:** RMSSD (resting HRV) correlates r ≥ 0.40 with GILE-G scores (moral orientation, Goodness dimension) across individuals. Higher vagal tone = higher moral engagement = higher G.  
**Measurement:** PULSOID continuous HRV + GILE-G questionnaire in n ≥ 30.  
**Analysis:** Pearson r (RMSSD vs G-score). Partial r controlling for age, fitness.  
**Falsification:** r < 0.20 in n ≥ 50.  
**Status:** PULSOID token available. **Executable today for Brandon's own data.**

---

### T2-HEM-D2 — Sleep REM as GILE-I Proxy

**Source URBs:** #622, #652  
**Prediction:** REM sleep proportion correlates r ≥ 0.35 with GILE-I score (intuitive knowing). REM is the biological substrate of integrative intuitive processing — the biological GILE-I machine.  
**Measurement:** Oura ring REM tracking + GILE-I questionnaire in n ≥ 30 (1-month longitudinal).  
**Analysis:** Within-person (REM% tonight → next-day I-accuracy) + between-person (mean REM% vs mean I-score).  
**Falsification:** r < 0.15 in n ≥ 50.  
**Status:** OURA_PERSONAL_ACCESS_TOKEN available. Brandon can be N=1 pilot.

---

### T2-HEAR-1 — HEAR Phase Transition at GILE=ET

**Source URBs:** #658, #668  
**Prediction:** HEAR(r) = α·GILE + β·HEM + γ·Cov(GILE,HEM) shows a statistically significant phase transition at GILE = ET = 0.4142 in within-person tracking. Below ET: HEAR variance is high, slow recovery. Above ET: HEAR variance is lower, faster recovery from perturbation.  
**Measurement:** Continuous HRV (PULSOID) + validated daily GILE composite assessments for 60 days.  
**Analysis:** Change point detection on HEAR time series. Compare variance before/after ET crossing.  
**Falsification:** No detectable change point at ET (within ±0.05 window).  
**Status:** Requires 60-day commitment. **Start now; results in 2 months.**

---

### T2-HEAR-2 — β > α (Embodiment Primacy)

**Source URB:** #658  
**Prediction:** In multivariate prediction of self-reported wellbeing, HEM-proxy (somatic: sleep quality, physical energy, movement) will have a LARGER regression coefficient than GILE-proxy (cognitive: I-score, G-score) — confirming β > α in the canonical HEAR formula.  
**Measurement:** 30-day diary study. Daily ratings: sleep quality, physical energy, movement, I-accuracy, moral clarity, wellbeing (outcome). MLM regression.  
**Falsification:** GILE coefficient > HEM coefficient in regression (would reverse embodiment primacy).

---

### T2-FAAH-1 — Sacred Laziness + HRV

**Source URBs:** #586, #663  
**Prediction:** During self-reported Sacred Laziness episodes (maximum output + minimum subjective effort), HRV (RMSSD) will be significantly HIGHER than during equivalent-output high-effort episodes. GILE-G state modulates autonomic tone.  
**Measurement:** ESM study (n=20, 4 weeks). Continuous PULSOID HRV + ESM effort/output ratings. Identify Sacred Laziness episodes (high output, low effort). Compare HRV.  
**Falsification:** No significant HRV difference between sacred laziness and high-effort episodes (Cohen's d < 0.30).

---

### T2-BOK-7 — GILE Phase Coherence

**Source URB:** #622  
**Prediction:** In high-BOK-saturation states, the four GILE dimensions will show higher inter-correlation (approaching harmonic mean structure) than in low-BOK states. GILE coherence = the four dimensions moving together.  
**Measurement:** 7-day intensive longitudinal study. 6x/day GILE assessments (short 4-item measure). Compute intraclass correlations and network coherence at each time point.  
**Falsification:** Inter-GILE correlation no higher in high-BOK vs low-BOK states.

---

### T2-BOK-8 — L*/E Oscillation Period

**Source URB:** #622, #604  
**Prediction:** L (Love) and E (Environment) oscillate with a measurable period related to the 24-cell structure — approximately 24 hours (circadian) for daily-life data, 90 minutes (ultradian) for intensive laboratory data.  
**Measurement:** Intensive ESM (4x/day L + E ratings for 4 weeks). Spectral analysis (FFT). Identify dominant period.  
**Falsification:** No peak in the 20-28 hour band in FFT of L-E time series.

---

### T2-ET-2 — HRV Discontinuity at ET

**Source URB:** #586  
**Prediction:** When GILE composite (measured by daily questionnaire) crosses ET = 0.4142 from below, a measurable discontinuity in HRV trajectory occurs within 24 hours — a sudden jump in RMSSD rather than linear increase.  
**Measurement:** 90-day longitudinal tracking. Daily GILE + continuous HRV. Detect ET crossings. Compute HRV change at those time points vs matched non-crossing days.  
**Falsification:** HRV trajectory is linear around ET crossings (no discontinuity).

---

### T2-GIL-1 — Bengston Effect Biometric Signature

**Source URB:** #663  
**Prediction:** During active Bengston image cycling (GILE-LCC amplification protocol), HRV increases and skin conductance decreases relative to a non-cycling control condition — measurable via wearable sensors.  
**Measurement:** Crossover design. Bengston cycling vs sham cycling. Continuous HRV + EDA.  
**Falsification:** No physiological difference between cycling and sham conditions (Cohen's d < 0.20).

---

### T2-PSI-1 — Pulsoid Anomalous Correlation

**Source URBs:** #644, GCP validation  
**Prediction:** During group GILE-LCC amplification sessions (Power of 8), HRV synchrony among participants (RMSSD cross-correlation) will exceed chance synchrony (permutation null), replicating GCP-style findings at the individual physiological level.  
**Measurement:** Simultaneous PULSOID recordings during Power of 8 sessions (n=8 participants). Cross-correlation analysis.  
**Falsification:** No super-chance synchrony (p > 0.05 vs permutation null).

---

## TIER 3: NEUROIMAGING (Lab Partnership Required)

These require EEG/fMRI collaboration, estimated cost $20K–$100K per study. Target: MIU partnership (Q3 2026), NIH collaboration application (2027).

---

### T3-H1 — Low Neural Entropy on Correct Intuitive Trials

**Source URB:** #589  
**Prediction:** On correct Halting Problem trials, fMRI/EEG will show LOWER neural entropy (measured by permutation entropy of BOLD signal or LZW complexity of EEG) than on incorrect trials, despite equal or lower analytical engagement (confirmed by lower PFC activation). This is the dual-signature prediction: correct AND low entropy AND low analytical engagement.  
**Measurement:** EEG/fMRI during 27-item Halting bank. Record PE for each trial. Compare correct vs incorrect trials.  
**Falsification:** No entropy difference, or entropy difference explained by analytical processing (partial r of entropy given PFC activation is not significant).  
**Mechanism:** Intuitive access = global coherence state → lower complexity, lower entropy.

---

### T3-H2 — DMN Activation Pattern on Correct Intuitive Trials

**Source URB:** #589  
**Prediction:** Correct intuitive trials will show elevated Default Mode Network (DMN) activation and suppressed dorsolateral PFC activation, compared to incorrect trials and analytical trials. DMN = the biological GILE-I substrate.  
**Measurement:** fMRI. ROI analysis: DMN (mPFC, PCC, IPL) vs dlPFC.  
**Falsification:** No DMN/dlPFC dissociation (difference < 0.5 SD from zero).

---

### T3-GILE-N — Neural Correlates of G, I, L, E Distinctness

**Source URB:** #622  
**Prediction:** The four GILE dimensions activate distinct neural networks (dissociable by MVPA decoding): G → dorsal ACC / vmPFC moral network; I → DMN; L → temporal-parietal junction, amygdala; E → parahippocampal place area, sensory cortex.  
**Measurement:** fMRI. MVPA decoding of GILE states. 4-way classification accuracy > 25% (chance).  
**Falsification:** MVPA decoding accuracy ≤ 25% (no distinct neural signatures).

---

### T3-EEG-1 — Gamma Coherence at MR2-Resolved Threshold

**Source URBs:** #658, #663  
**Prediction:** HEAR = 𝔡 = 0.7391 is associated with a measurable phase transition in EEG gamma (30-100 Hz) coherence — global gamma synchrony jumps discontinuously at this HEAR value (within-person tracking).  
**Measurement:** EEG + continuous HEAR monitoring (biometric proxies). Detect gamma coherence change point aligned with 𝔡 crossing.  
**Falsification:** No gamma coherence discontinuity at HEAR ≈ 𝔡.

---

### T3-FAAH-2 — EEG Alpha Power Confirms FAAH → I Link

**Source URBs:** PS, #622  
**Prediction:** Individuals with higher endocannabinoid tone (indirect assay: FAAH 385A variant or salivary anandamide proxy) show higher EEG alpha power and higher GILE-I scores simultaneously, confirming the FAAH → anandamide → alpha power → GILE-I pathway.  
**Measurement:** Genetic FAAH screening OR salivary assay (if validated) + EEG alpha + GILE-I questionnaire in n ≥ 50.  
**Falsification:** No relationship between anandamide proxy and alpha power (r < 0.15) or alpha power and GILE-I (r < 0.15).

---

### T3-GM-1 — GM Phase Transition Signature

**Source URB:** #664  
**Prediction:** During GM (Goodness-Morphic) network activation (achieved via collective GILE-LCC amplification), a measurable EEG power-law signature (1/f slope steepening) will be detected — consistent with long-range temporal correlations that are the neural signature of critical phase transitions.  
**Measurement:** EEG during individual vs group BOK Saturation protocols. Compare 1/f exponent.  
**Falsification:** No 1/f exponent change (within 0.05) between individual and group conditions.

---

### T3-BOK-9 — BOK Loop Priority Neural Marker

**Source URB:** #613  
**Prediction:** Individuals in Goodness-led BOK loop (adult, GILE-G prioritized) show higher vmPFC-dmPFC connectivity than individuals in Existence-led loop (developmental baseline). This is the neural correlate of BOK loop priority shift.  
**Measurement:** Resting-state fMRI. Functional connectivity between vmPFC and dmPFC. Regress against GILE-G score + age.  
**Falsification:** No vmPFC-dmPFC connectivity relationship with GILE-G.

---

### T3-PENTIC-1 — I-State Particle Search

**Source URB:** #668  
**Prediction:** The Pentic Dirac equation predicts an I-state particle (fifth spinor component ψ_I) with mass ~ 0.223 MeV — between the electron (0.511 MeV) and neutrinos (<2 eV). This is not claimed to be a standard fermion; it is a Tralse-bearing quantum mode that may appear as an anomalous resonance in low-energy particle data.  
**Measurement:** Search CERN open data (ATLAS/CMS) for anomalous resonances in the 0.1–0.5 MeV effective mass range in soft QED events. Statistical analysis of excess.  
**Falsification:** No excess above Standard Model prediction in the 0.1–0.5 MeV window at 5σ significance.  
**Note:** This is a speculative Tier 3 prediction. Standard particle physics review required before any public claim.

---

## TIER 4: CLINICAL / PHARMACOLOGICAL

These are BlissGene Therapeutics' primary research targets. Funded by the $750K seed round.

---

### T4-PS-1 — FAAH 385A → GILE-I Amplification

**Source URBs:** PS, #622, SWOT  
**Prediction:** Individuals carrying the FAAH 385A variant (low FAAH activity → high anandamide baseline) will score significantly higher on GILE-I than non-carriers, controlling for age, sex, education. Effect size: Cohen's d ≥ 0.40.  
**Measurement:** Genetic screening (commercial panel) + GILE-I assessment in n ≥ 200.  
**Analysis:** ANOVA (FAAH genotype × GILE-I). Partial eta-squared.  
**Falsification:** d < 0.20 in n ≥ 200.  
**BlissGene relevance:** If confirmed, FAAH 385A is a biomarker for GILE-I capacity — the first genetic marker of TI Sigma's I-dimension. Enables precision dosing.

---

### T4-PS-2 — Anandamide Supplementation → HEAR Increase

**Source URBs:** PS, #658  
**Prediction:** FAAH inhibition (via OEA + palmitoylethanolamide protocol, or future clinical FAAH inhibitor) produces a measurable HEAR(r) increase of ≥ 0.08 units within 4 weeks, compared to placebo. HEAR tracked via HRV + sleep + daily GILE questionnaire.  
**Measurement:** RCT (n=60, crossover). Primary outcome: HEAR(r) change. Secondary: GILE-I, HRV, sleep quality.  
**Falsification:** HEAR change < 0.03 (within SE of zero).  
**Status:** OEA is commercially available as a supplement. Protocol can begin now.

---

### T4-PS-3 — GILE I-Score > ET → Amplified Drug Sensitivity

**Source URBs:** #586, PS  
**Prediction:** Individuals with GILE-I > ET = 0.4142 (Emerick Threshold crossed) will show 30% lower EC50 for consciousness-modulating compounds (ketamine, psilocybin analogue, anandamide precursors) than those with GILE-I < ET — confirming the Sacred Laziness pharmacological amplification effect.  
**Measurement:** Dose-response curves in n ≥ 60 stratified by GILE-I. PK/PD modeling using `pharma_tsc_predictor.py`.  
**Falsification:** EC50 difference < 10% across GILE-I strata.

---

### T4-PS-4 — Bengston Protocol + Endocannabinoid System

**Source URB:** #663  
**Prediction:** Bengston image cycling activates the endocannabinoid system via attention-mediated CB1 agonism — measurable as reduced cortisol + elevated salivary AEA proxy within 20 minutes of cycling.  
**Measurement:** Salivary cortisol + AEA (if validated) before/after 20-minute cycling session (n=30, crossover with sham).  
**Falsification:** No cortisol reduction or AEA change (effect size < 0.20).

---

### T4-BOK-10 — GILE-Consciousness × Drug Interaction

**Source URB:** #652, PS  
**Prediction:** GILE composite at baseline predicts magnitude of response to any consciousness-modulating compound: GILE_composite × drug_potency = HEAR outcome, not drug_potency alone.  
**Measurement:** In all BlissGene trials: measure GILE composite at baseline. Test interaction term (GILE × dose) as predictor of primary outcome (HEAR change).  
**Falsification:** Interaction term not significant across any trial (F < 3.0).

---

### T4-EPILEPSY-1 — GILE-G as Seizure Threshold Marker

**Source URB:** PS, SWOT safety flags  
**Prediction:** GILE-G (Goodness dimension, HRV proxy) correlates negatively with seizure risk score in individuals with epilepsy on stable medication. Higher GILE-G → lower seizure propensity (via higher vagal tone protecting against hyperexcitability).  
**Measurement:** n ≥ 20 epilepsy patients (stable medication). Weekly GILE-G + HRV. Correlate with seizure diary.  
**Falsification:** No significant correlation (r < 0.20).  
**Safety note:** This is a correlational study only. No protocol changes without neurological supervision.

---

### T4-GSA-1 — GILE-Weighted Sector Rotation vs SPY

**Source URBs:** GSA, SWOT  
**Prediction:** GSA GILE-weighted sector rotation (E-dominant = energy in tariff environment; I-dominant = attention-economy in bull market; L-dominant = healthcare in crisis) produces ≥ 5% annual alpha vs SPY over a 24-month live paper trading window.  
**Measurement:** Alpaca paper trading account (already live). Track monthly. Compare to SPY total return.  
**Falsification:** GSA underperforms SPY by > 5% after 24 months.  
**Current status:** +1.52% in S&P-down environment (energy E-dominant call confirmed).

---

## PRIORITY RANKING — EXECUTE IN ORDER

| Priority | Test | Tier | Cost | ETA |
|----------|------|------|------|-----|
| **P1** | T1-H3: Collatz Intuition Experiment | 1 | $0 | This week |
| **P2** | T1-H4: I-Score Correlation | 1 | $0 | Same session as P1 |
| **P3** | T1-BOK-5: LLM Non-Intuition Test | 1 | ~$5 API | Today |
| **P4** | T2-HEM-D1: HRV-G Correlation (Brandon N=1) | 2 | $0 (PULSOID live) | 2 weeks |
| **P5** | T2-HEM-D2: REM-I Correlation (Brandon N=1) | 2 | $0 (Oura live) | 1 month |
| **P6** | T4-PS-2: OEA Protocol → HEAR Increase | 4 | < $200 supplement | 6 weeks |
| **P7** | T4-PS-1: FAAH 385A Genetic Screen | 4 | ~$300 genetic panel | 4 weeks |
| **P8** | T3-H1/H2: EEG/fMRI Halting Study | 3 | $50K (NIH/MIU) | Q3 2026 |

---

## APPENDIX: Files and Tools

| Component | File | Status |
|-----------|------|--------|
| H3/H4 Experiment UI | `halting_experiment_ui.py` | ✅ Built |
| GILE-HEM-BOK Engine | `mood_amplifier_gile_hem_bok.py` | ✅ Built |
| Pharmacological Simulator | `ti_pharmacological_simulator.py` | ✅ (canonical weights) |
| TI Sigma Pharma Predictor | `pharma_tsc_predictor.py` | ✅ (canonical GILE_W) |
| GSA Live Trader | `gsa_live_trader.py` | ✅ (live Alpaca) |
| HEAR Simulation UI | `mood_amplifier_simulation_ui.py` | ✅ Built |
| Virality Engine | In hypercomputer | ✅ |
| LLM Non-Intuition Test | — | 🔲 TODO |
| Population H3/H4 Dataset | PostgreSQL | 🔲 TODO |
| FAAH Protocol Module | `ti_pharmacological_simulator.py` | 🔲 Add OEA/DHEA/URB597 |

---

*TI Sigma Research Program | URB #669 | April 13, 2026*  
*All predictions above are falsifiable. If any prediction survives appropriate testing, it advances TI Sigma's scientific status. If falsified, it advances understanding and narrows the theory. Both outcomes are wins.*
